- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bionano Genomics Inc(BNGO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BNGO
11/20/2026: BNGO (1-star) is currently NOT-A-BUY. Pass it for now.
Bionano Genomics Inc is a life sciences instrumentation company that provides optical genome mapping systems and bioinformatics software to detect complex structural genomic variants. Its primary business strengths include pioneering technology like the Saphyr and Stratys platforms and sticky consumable flow-cell streams. The core investment opportunity centers on the transition of optical genome mapping into routine clinical diagnostics backed by expanding reimbursement. However, key risks include persistent operating losses, tight cash reserves, and intense competition from larger sequencing firms. The stock suits risk-tolerant growth investors willing to monitor clinical adoption milestones and cash management execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While operating in a high-growth genomics niche, revenue scaling has been uneven and offset by ongoing cash burn. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp episodic rallies driven by clinical milestones or adoption updates when technical momentum turns positive. |
| Value investor | Weak fit | The company lacks current profitability and positive net income, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Bionano Genomics does not pay dividends as it reinvests all capital into business operations. |
| Low-risk investor | Weak fit | High share price volatility and micro-cap status expose investors to significant capital risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock exhibits high beta and sensitivity to market sentiment and micro-cap liquidity swings. |
| Valuation risk | Medium / high | Valuation is heavily dependent on future revenue realization and long-term clinical adoption milestones. |
| Competition risk (next-generation sequencing and genomic analysis platforms) | High | Well-capitalized sequencing giants continuously advance alternative technologies that compete for lab budgets. |
| Business quality | Medium | Proprietary technology offers unique scientific utility, but financial scale and profitability remain constrained. |
| Dividend income | Low / none | No dividend is distributed to shareholders. |
| Execution risk | High | Success relies heavily on commercial execution, lab workflow integration, and securing broader reimbursement. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.50M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 246.3K shares | Beta 1.71 | 52 Weeks Range 0.81 - 2.23 | Updated Date 11/20/2026 |
52 Weeks Range 0.81 - 2.23 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Instruments & Supplies
- BUY participation
- 50.0%
- Active BUY / eligible
- 1 / 2
- 30-Day BUY Count Change
- +1
Eligible universe: 2 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -54.76% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Instrument Systems | Sales and leases of Saphyr and Stratys optical genome mapping hardware instruments to research and clinical labs. | Upfront hardware sales establish the installed base that drives future recurring consumable usage. |
| Consumables | Flow cells, labeling kits, and reagent packs consumed during routine sample processing on Bionano hardware. | Provides a sticky, recurring revenue stream as laboratory testing volume scales over time. |
| Services and Software | Software licenses for NxClinical bioinformatics platforms, support contracts, and genomic analysis services. | Enhances product stickiness by providing essential data analysis and clinical reporting tools. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12.03M | Price to Sales(TTM) 0.37 |
Enterprise Value 12.03M | Price to Sales(TTM) 0.37 | ||
Enterprise Value to Revenue 0.39 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 13.99M | Shares Floating 12.81M |
Shares Outstanding 13.99M | Shares Floating 12.81M | ||
Percent Insiders 2.32 | Percent Institutions 25.12 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

